Evommune, Inc. (EVMN)

Evommune Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023
Cash & Equivalents	26.82	16.26	29.02
Short-Term Investments	49.24	55.79	50.06
Cash & Short-Term Investments	76.06	72.04	79.08
Cash Growth	-3.82%	-8.91%	-
Prepaid Expenses	3.78	1.95	0.95
Total Current Assets	81.94	73.99	80.03
Property, Plant & Equipment	1.13	1.8	1.97
Other Long-Term Assets	1.47	0.27	0.25
Total Assets	84.54	76.06	82.25
Accounts Payable	3.58	8.26	1.76
Accrued Expenses	6.31	6.73	4.03
Current Portion of Leases	0.5	0.86	0.77
Current Unearned Revenue	-	3	-
Other Current Liabilities	0.03	9.13	0.3
Total Current Liabilities	10.42	27.98	6.86
Long-Term Leases	0.26	0.52	0.49
Long-Term Deferred Tax Liabilities	-	-	3
Other Long-Term Liabilities	-	0.02	0.25
Total Liabilities	10.68	28.52	10.59
Common Stock	-	0	0
Additional Paid-In Capital	9.68	7.98	6.2
Retained Earnings	-192.82	-152.22	-83.91
Total Common Equity	-183.14	-144.24	-77.71
Shareholders' Equity	73.87	47.54	71.66
Total Liabilities & Equity	84.54	76.06	82.25
Total Debt	0.77	1.38	1.26
Net Cash (Debt)	75.3	70.66	77.83
Net Cash Growth	-3.25%	-9.21%	-
Net Cash Per Share	48.98	46.85	62.10
Filing Date Shares Outstanding	31.52	1.55	1.25
Total Common Shares Outstanding	1.55	1.55	1.25
Working Capital	71.53	46.01	73.18
Book Value Per Share	-117.78	-92.97	-62.01
Tangible Book Value	-183.14	-144.24	-77.71
Tangible Book Value Per Share	-117.78	-92.97	-62.01

Updated Oct 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q